APA (7th ed.) Citation

Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., . . . Group, E. S. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Publishing Group.

Chicago Style (17th ed.) Citation

Martin, M., et al. Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. The Lancet Publishing Group, 2017.

MLA (9th ed.) Citation

Martin, M., et al. Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. The Lancet Publishing Group, 2017.